Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
Patrick W Serruys, John A Ormiston, Georgios Sianos, J Eduardo Sousa, Eberhard Grube, Peter den Heijer, Pim de Feyter, Pawel Buszman, Albert Schömig, Jean Marco, Lech Polonski, Leif Thuesen, Andreas M Zeiher, JH Nicholas Bett, Maarten J Suttorp, Helmut D Glogar, Mark Pitney, Gerard T Wilkins, Robert Whitbourn, Susan Veldhof Show all
Journal of the American College of Cardiology | Published : 2004
OBJECTIVES: We sought to demonstrate the safety and performance of the actinomycin D-coated Multilink-Tetra stent(Guidant Corp., Santa Clara, California) in the treatment of patients with single de novo native coronary lesions. BACKGROUND: Drug-eluting stents (DES) releasing sirolimus or paclitaxel dramatically reduce restenosis. The anti-proliferative drug, actinomycin D, which is highly effective in reducing neointimal proliferation in preclinical studies, was selected for clinical evaluation. METHODS: The multi-center, single-blind, three-arm ACTinomycin-eluting stent Improves Outcomes by reducing Neointimal hyperplasia (ACTION) trial randomized 360 patients to receive a DES (2.5 or 10 mi..View full abstract